Back

Apoptosis-coupled senescence causes cancer cell senotherapy

Youn, B.-S.

2023-09-23 cancer biology
10.1101/2023.09.22.558973 bioRxiv
Show abstract

Although new generations of anti-cancer modalities have been accumulated involving immuno-oncology cancers remain prevailing. This implies the current understanding of cancer cell biology is far from satisfactory. Curation of cancers is extremely rare. We hypothesized what could be the easiest Achilles Hill of cancer cells such that simple administration can jab cancer cells to be knocked out. Of conspicuous differences between cancer cells and normal cells, for example, metabolism, hypoxia, anaerobic glycolysis, uncontrolled cell proliferation, etc. exist. What could be the easiest and the most reliable anti-cancer modalities? We discovered one was cancer cell senescence (CCS) because cancer cells are the most presenescent (old) cells. We utilized a synthetic polyphenol designated as ONG41008. ONG41008 was able to induce massive senescence of pathologic myofibroblasts (pMFBs) and a vast majority of representative human cancer cells as well as a line of primary NSCLCs. All these cells turned out to be senescence-associated beta-galactosidase (SAbGAL) positive to different degrees, which does not mean real senescence is occurring in these cells. ONG41008 did not harm normal cells and elicited massive senescence in pMFBs without apoptosis. However, ONG41008 caused massive senescence as well as apoptosis in cancer cells. In other words, ONG41008 was capable of sensing intracellular molecular environments between normal cells, cancer cells, and pMFBs. This molecular recognition capability prompted us to explore how ONG4008 behaved on A549 (a human lung adenocarcinoma), PANC1(malignant human ductal adenocarcinoma), and mdr+PC3 (multidrug-resistant human prostate cancer). TP53, p21, and p16 were induced and/or nuclear relocated, suggesting that ONG41008 was recognized by these cells. ONG41008 drove A549 and PANC1 at G2/M phase arrest during 48 hrs, resulting in massive mitotic collapse. All cells died. Moreover, the cisplatin-resistant mdr+PC3 was also eliminated by ONG41008. An array of common components of apoptosis were activated, and especially, induction of Mcl1 was especially notable. These senolytics features were reported to oncogene-induced-senescence (OIS), in which the expression of over two activated oncogenes in the embryonic fibroblasts caused massive senescence and cell death as well. And the signature expression of Mcl1, an anti-apoptotic protein (a long form), was notable but two kinds of short forms are pro-apoptotic proteins. OIS was conducted in vitro cell culture models and whether or not the presence of OIS counterpart in vivo remains to be delineated. Taken together, we discovered a synthetic polyphenol referred to as ONG41008 was both senogenic and senolytic and its senescent impacts may make the cell cycles of the ONG41008-treated cancer cells immensely arrested at the G2/M phase, leading to mitotic slippage and cell death. This interesting observation may be able to create an idealistic anti-cancer modality, specifically killing cancer cells, but normal cells remain unharmed.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Aging
75 papers in training set
Top 0.1%
12.1%
2
PLOS ONE
5266 papers in training set
Top 17%
11.2%
3
Pharmaceuticals
34 papers in training set
Top 0.1%
8.0%
4
Life Sciences
27 papers in training set
Top 0.1%
5.6%
5
International Journal of Molecular Sciences
494 papers in training set
Top 2%
4.1%
6
Scientific Reports
3612 papers in training set
Top 31%
3.3%
7
Translational Oncology
21 papers in training set
Top 0.1%
3.3%
8
Cell Death Discovery
58 papers in training set
Top 0.2%
3.3%
50% of probability mass above
9
Biomedicines
67 papers in training set
Top 0.4%
2.8%
10
Frontiers in Oncology
103 papers in training set
Top 1%
2.7%
11
Journal of Translational Medicine
57 papers in training set
Top 0.8%
1.7%
12
Experimental Cell Research
28 papers in training set
Top 0.3%
1.5%
13
eLife
5828 papers in training set
Top 51%
1.5%
14
npj Aging
22 papers in training set
Top 0.3%
1.5%
15
Cells
249 papers in training set
Top 4%
1.5%
16
Biochemical and Biophysical Research Communications
84 papers in training set
Top 1%
1.5%
17
Biochemistry and Biophysics Reports
30 papers in training set
Top 0.6%
1.4%
18
Frontiers in Pharmacology
111 papers in training set
Top 2%
1.1%
19
Heliyon
152 papers in training set
Top 5%
1.1%
20
Frontiers in Medicine
120 papers in training set
Top 3%
1.1%
21
Cellular and Molecular Life Sciences
96 papers in training set
Top 2%
1.0%
22
Journal of Investigative Dermatology
49 papers in training set
Top 0.5%
0.9%
23
Cancer Medicine
26 papers in training set
Top 1%
0.9%
24
Cell Death & Disease
126 papers in training set
Top 3%
0.9%
25
iScience
1154 papers in training set
Top 33%
0.9%
26
PeerJ
308 papers in training set
Top 11%
0.9%
27
Advanced Biology
29 papers in training set
Top 0.7%
0.9%
28
Molecules
39 papers in training set
Top 1%
0.9%
29
Cancers
213 papers in training set
Top 5%
0.9%
30
Biochemical Pharmacology
20 papers in training set
Top 0.5%
0.6%